Table 1 Patient’s Demographics and Cancer Treatment Characteristics Based on Transfusion Status
|  | Transfused (n = 78) | Not Transfused (n = 270) | p-value |
|---|---|---|---|
Age * | 67 ± 9 years | 65 ± 9 years | 0.09 |
Gender | 12 (15%) Female | 62 (23%) Female | 0.16 |
66 (85%) Male | 208 (77%) Male | ||
Anemic at Diagnosis** 120/289 (42%) | 41 (61%) | 79 (36%) | 0.0002 |
Clinical T Stage | 1 8 (12%) 2 7 (10%) 3 51 (75%) 4 2 (3%) | 1 31 (14%) 2 32 (14%) 3 164 (72%) 4 0 (0%) | 0.26 |
Tumor Histology | 12 (16%) Squamous 65 (84%) Adenoca | 37 (11%) Squamous 288 (89%) Adenoca | 0.33 |
Treated with NARx | 53 (68%) | 163 (60%) | 0.70 |
Diagnosis to OR (days)*,$ | 130 ± 2 days | 136 ± 39 days | 0.39 |
Complete Response (CR) to NARx$ | 12 (23%) | 66 (40%) | P = 0.021 |
Anemic Pre-operative** 216/338 (64%) | 67 (86%) | 149 (57%) |  < 0.0001 |
Estimated Blood Loss (EBL)* | 383 ± 274 ml | 257 ± 166 ml |  < 0.0001 |
Pathologic/Surgical T Stage | 0 13 (17%) 1 15 (19%) 2 17 (22%) 3 30 (38%) 4 2 (3%) In-Situ 1 (1%) | 0 69 (26%) 1 70 (26%) 2 44 (16%) 3 83 (31%) 4 0 (0%) In-Situ 3 (1%) | P = 0.032 |
Lymph Node Status | 50 (64%) Negative | 172 (64%) Negative | 1.00 |
28 (36%) Positive | 97 (36%) Positive | ||
Hospital Length of Stay * | 19 ± 20 days | 9 ± 4 days |  < 0.0001 |